# Boston Scientific Moat

Status: published. Policy: company-analysis-1.

Boston Scientific demonstrates sustained product demand and successful commercialization, but the passages do not establish how long its technology, patents or physician familiarity protect it from competition. Increased competition has already affected Electrophysiology sales. Pricing power remains unproven because reported improvements combine pricing, volume, mix and temporary benefits, while purchasing consolidation constrains discretion. This is insufficient evidence of a durable moat, rather than evidence of a broadly weak competitive position.

## intangible_assets

Existing patents and commercially successful technologies are potential sources of protection. Growth from Farapulse, WATCHMAN and AGENT demonstrates adoption, but does not establish durable superiority or exclusion of rivals.

Durability: Unestablished: the passages disclose neither economically important patent expiration schedules nor sustained comparative clinical advantages. Regulatory approval costs create industry barriers without establishing Boston Scientific's advantage over established competitors.

Risks: Competition has affected Electrophysiology sales; patent circumvention, reimbursement changes and competing technologies could weaken differentiation. Acquired research projects represent future potential.

Invalidation: Sustained product-level share losses, adverse comparative clinical results, invalidation or circumvention of important patents, or loss of reimbursement would undermine the proposed protection. Sustained share and adoption despite competing launches would strengthen it.

Competitors: Abbott Laboratories, Medtronic plc
## switching_costs

Physician familiarity may support repeat demand, but the disclosure identifies it as a competitive factor without demonstrating retraining costs, exclusive workflows or customer dependence.

Durability: Potential rather than established. Continuing franchise demand supports adoption but cannot distinguish customer retention from new procedures and new customers.

Risks: Consolidated purchasing, tenders and competing products can override physician preferences. WATCHMAN procedure deceleration is a demand caution, without proof of customer switching.

Invalidation: Demonstrated rapid substitution by hospitals or physicians without meaningful retraining or disruption would invalidate material switching costs; documented repeat purchasing and costly conversion would support them.

Competitors: Abbott Laboratories, Medtronic plc
- [https://www.sec.gov/Archives/edgar/data/885725/000088572526000010/bsx-20251231.htm](https://www.sec.gov/Archives/edgar/data/885725/000088572526000010/bsx-20251231.htm) · 2026-02-17
- [https://www.sec.gov/Archives/edgar/data/885725/000088572526000053/bsx-20260630.htm](https://www.sec.gov/Archives/edgar/data/885725/000088572526000053/bsx-20260630.htm) · 2026-08-03
- [https://www.sec.gov/Archives/edgar/data/885725/000088572526000025/bsx-20260318.htm](https://www.sec.gov/Archives/edgar/data/885725/000088572526000025/bsx-20260318.htm) · 2026-03-18
- [https://www.sec.gov/Archives/edgar/data/885725/000088572525000011/bsx-20241231.htm](https://www.sec.gov/Archives/edgar/data/885725/000088572525000011/bsx-20241231.htm) · 2025-02-18
- [https://www.sec.gov/Archives/edgar/data/885725/000088572524000017/bsx-20231231.htm](https://www.sec.gov/Archives/edgar/data/885725/000088572524000017/bsx-20231231.htm) · 2024-02-20
- [https://www.sec.gov/Archives/edgar/data/885725/000088572526000033/bsx-20260331.htm](https://www.sec.gov/Archives/edgar/data/885725/000088572526000033/bsx-20260331.htm) · 2026-05-01

[JSON](https://beanvest.com/stock/bsx/moat.json)